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High levels of factor IX increase the risk of venous thrombosis
Astrid van Hylckama Vlieg, Irma K. van der Linden, Rogier M. Bertina, and Frits R. Rosendaal
Elevated plasma levels of factor VIII
(> 150 lU/dL) are an important risk factor
for deep vein thrombosis (DVT). Factor
VIII is the cofactor of factor IXa in the
activation of factor X. The risk of thrombo-
sis in individuals with an elevated factor
IX level is unknown. This study investi-
gated the role of elevated factor IX levels
in the development of DVT. We compared
426 patients with a first objectively diag-
nosed episode of DVT with 473 popula-
tion controls. This study was part of a
large population-based case-control study
Introduction
on risk factors for venous thrombosis,
the Leiden Thrombophilia Study (LETS).
Using the 90th percentile measured in
control subjects (P9o = 129 U/dL) äs a
cutoff point for factor IX levels, we found
a 2- to 3-fold increased risk for individu-
als who have factor IX levels above 129
U/dL compared with individuals having
factor IX levels below this cutoff point.
This risk was not affected by adjustment
for possible confounders (age, sex, oral
contraceptive use, and high levels of
factor VIII, XI, and vitamin K-dependent
proteins). After exclusion of individuals
with known genetic disorders, we still found
an odds ratio (OR) of 2.5 (95% confidence
interval [Cl]: 1.6-3.9). The risk was higher in
women (OR: 2.6, Cl: 1.6-4.3) than in men
(OR: 1.9, Cl: 1.0-3.6) and appeared highest in
the group of premenopausal women not
using oral contraceptives (OR: 12.4, Cl:
3.3-47.2). These results show that an ele-
vated level of factor IX is a common risk
factor for DVT. (Blood. 2000;95:3678-3682)
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The incidence of deep vein thrombosis (DVT) in the general
population is ahout l in 1000 people per year. '2 The pathogenesis
of DVT is complex. In theory. hyperactive coagulation pathways,
hypoactive anticoagulant mechanisms. o r hypoactive fibrinolysis
may cause the development of DVT.'
Risk factors can bc classiüed into acquired and genetic factors.4
DVT is a multicausal disease; that is, more than a single risk factor
needs to be present simultaneously to cause thrombosis.5·6 Known
acquired risk factors include immobilization, surgery, trauma,
pregnancy. puerperium. lupus anticoagulant. malignant disease.
and female hormones.17 Genetic risk faclors causing a tcndency to
DVT arc anti thrombin deficiency,s protein C deh'ciency.9 protein S
deficicncy.10 the factor V Leiden mutation." and the prothrombin
20210 A al lele .1 2 However, in about 30% of patients with a family
history of DVT. no underlying genetic defect will be found. "
Other risk factors that are frequently reported among patients
with DVT are elevated factor VIII levels14 and hyperhomocystei-
nemia.15 ·16 We recently found that elevated levels of factor XI17 and
faclor X in women who do not use oral contraceptives18 are also
associated with the risk of thrombosis. The molecular basis of these
abnormalities is still unknown. Because faclor VIII is the cofactor
of factor IXa in the activalion of factor X, it seemed plausible that
elevaled levels of factor IX could also be a risk factor for DVT.
Factor IX plays a key role in hemoslasis; it is a vitamin
K-dependent glycoprotein, which is activated through the intrinsic
pathway äs well äs the extrinsic pathway.19 Factor IX, when
activated by factor XIa or factor Vlla-tissue factor. converts factor
X into Xa and this eventually leads to the formation of a fibrin clot.
This conversion is accelerated by the presence of the nonenzymatic
cofactor factor Villa, calcium ions, and a phospholipid mern-
brane.20 In healthy individuals. factor IX activity and antigen levels
vary between 50% and 1509r of that in pooled normal plasma.21
Several studies have reported that factor IX levels increase with
age-2-24 äs well äs with oral contraceptive use.23·25 Deficiencies of
factor VIII (hemophilia A) and factor IX (hemophilia B) lead to
clinically identical bleeding tendencies. Analogy suggests similar
effects of high levels of both clotting factors on thrombotic risk.
In this study. we investigated the role of elevated coagulation
factor IX levels in the development of a first DVT. The study was
part of a large population-based case-control study on risk factors
of venous thrombosis, the Leiden Thrombophilia Study (LETS).
Patients, materials, and methods
Study design
The design of this study has been described in detail previously.-'': In
short. we included 474 consecutive patients younger than 70 years with an
objectively confirmed first episode of DVT lhat occurred in the penod
between January 1988 and Deccmber 1992, who were selected froni the
files of the anticoagulation clinics in Leiden. Amsterdam, and Rotterdam.
These clinics monitor outpatient anticoagulant treatment in well-delinal
geographical areas. Patients with known malignant disorders were e\-
cluded. Each thrombosis patient was asked to find bis or her own contiol
subject with the same sex and approximately the same age (within 5 yeai^.
Partners of patients were also asked if they were willing to participate in th i i
study äs a control subject: if a patient was unable to find a control subieu.
the first individual on the list of partners matching for sex and age ua·.
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asked to join the study: 474 control subjects were included. Blood was
collected from the antecubital vein into Starstedt Monovette tuhes. in 0.1
volume 0.106 mol/L trisodium citrate. Plasma was preparcd by centrifuga-
tion for 10 minutes at 2000# at room temperalure and slored at — 70°C. unt i l
used. Patients and controls were seen concurrently and all samples wcre
analyzed with the same hatch of reagents. using the same pooled normal
plasma within a 6-week period.
Forty-eight of the patients and l of the control subjects were on
long-term oral anticoagulant therapy and. because this results in reduced
levels of the Vi tamin K-dependem proteins. they were excluded from the
analysis. For the current analysis. we thereforc studied 426 patients and 473
control subjects. The median time between thrombosis and venipuncture for
this study was 18 months (ränge. 6-56 months).
Measurement of factor IX
The levels of factor IX \\ere determined b\ enzyme-linked immunosorbent
assay (ELISA). This EL1SA is highly specihc for factor IX and results are
not affected by the levels of the other v i tamin K-dependent proteins.
PVC-microtiter plates (ICN Biomedicals BV. Zoctermeer. The Nether-
lands) were coated with rabbit antifactor IX antibodies äs capture antibodies
(DAKO A/S. Glostrup. Dcnmark; 3 μg/mL. 100 pL/well). Bound factor IX
was detected with non-Ca " -dependent antifactor IX IgG2s conjugated to
horseradish peroxidase (HRP). HRP a c t i \ i t y was measured with
o-phenylenediamine. The color reaction was stopped after 15 minutes us ing
H2SO4 and read spectrophotometrically at 492 um. The assay was
calibrated with dilutions of pooled normal plasma (1:25-1:1600). Plasmas
were diluted in washing buffer (50 mmol/L tnethanolainine, pH 7.5. 100
mmol/L NaCl. 10 mmol/L EDTA. 0. l 7r Tween). The faclor IX content of a
plasma sample was calculated äs the mean result ot single determinations of
3 different dilutions ( l : 100. l :200, and 1:400). Results were accepted when
the coefficient of Variation (CV) was less than 10%. Undertheseconditions.
the intra-assay and interassay CV was T/r (n = 9) and 7.2% (n = 41) ,
respectively, at a factor IX antigen level of about 100 U/dL. Results are
expressed in units perdeciliter. where l U is the amount of factor IX present
in l mLpooled normal plasma.
Because of the presence of EDTA in the buffer. only antibodies against
the non-Ca+~-dependent conformation of tactor IX are used. Therefore
results will not be influenced by variations in the degree of γ-carboxylation
of factor IX and represent t ruly factor IX protein concentrations in plasma.
Identical results can be obtained by us ing commercial antifactor IX-HRP
(Enzyme Research Laboratories. South Bend. IN) or commercial factor IX
ELISA. provided that EDTA is present in or added to the buffer system.
Factor VII and VIII were measured by 1-stagc coagulation assays.14·29
Prothrombin levels were measured by a chromogenic assay using Ecliif,
curinatus venom äs activator.12 Factor X antigen was measured by a
sandwich ELISA using commercial polyclonal antibodies (DAKO A/S)18
and factor XI antigen by an ELISA using a monoclonal antifactor XI
antibody äs catching antibody and polyclonal antifactor XI äs tagging
antibody.17
The technician was blmded concernmg the origin of the sample, (hat is.
whether it was from a patient or from a control subject.
Statistical analysis
The study was divided into 2 parts. First we investigated possible
determinants of factor IX levels. looking only at the control subjects äs
refiecting the general population. The determinants were established mainly
by comparing means and using linear regression. To assess the relationship
between factor IX levels and oral contraceptive use. an extra selection was
made in the study population. äs described earlier."1·31 We selected
nonmenopausal women between 15 and 49 years of agc. Women who were
at the index date (similar date äs t imc of thrombosis for patients) pregnant
(n = 10), within 30 days postpartum (n = 14). who had a recent miscar-
riage (n = 2), or had used only depol contraceptives (n = 3) were excluded.
A total of 153 control subjects were left for this specific analysis.
Secondly, we investigated vvhether a high level of factor IX is a risk
factor for DVT by calculatmg the adds ratio (OR) and the 95% confidence
interval (Cl). As a cutoff point wc used the 90th percentile of factor IX
levels measured in the control subjects. The factor IX levels were also
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divided in strata lo assess a relationship between factor IX levels and the
thrombosis risk (dose response).
To adjust for possible confounders, for example. age, sex. oral
contraceptive use at the time of thrombosis äs well äs at the time of
venipuncture, and high levels of factor VIII, XI, and the vitamin K-dependent
clotling factors (all dichotomized at the 90th percentile), we used a logistic
regression model. In case of sparse data (ie, known genetic risk factors for
thrombosis. oral contraceptive use). we also used restriction, that is,
analysis only of thosc without thrombophilic risk factors, only of men, or
only of women (premenopausal and postmenopausal) who did not change
thcir oral contraceptive use since their thrombosis (and who were not
pregnant. not within 30 days postpartum, did not have a recent miscarriage.
nor used only depot oral contraceptives). The thrombophilic risk factors
used in the restriction wcre protein C deficiency (< 0.67 U/mL), protein S
deficiency (< 0.67 U/mL). antithrombin deficiency (< 0.80 U/mL), the
factor V Leiden mutation, and the prothrombin 20210 A allele.32
Because tactor VIH is the cofactor of factor IX and itself a risk factor for
thrombosis.14 we assessed the effect on the thrombotic risk of elevated factor IX
levels alone and of elevated factor IX levels in combination with elevated factor
Vfll levels.
Results
The mean age of patients and controls at the time of the thrombosis
was 45 years (ränge, patients 15-69; controls, 15-72). Among cases
and controls alike, 59% were women.
Determinants of factor IX levels
The mean (ränge) of factor IX levels was 103 (52-188) U/dL. As
shown in Table l , factor IX levels increased with age, only after the
age of 55; factor IX levels were almost equal in men and in women
(mean difference: 3.4 U/dL, CI: —0.4 to 7.2). No difference was
found in factor IX levels between blood groups. Factor IX levels
were weakly associated with factor VIII and factor XI levels
(regression coefficient with factor IX level äs dependent variable,
factor VIII: 0.18, CI: 0.12-0.24 and factor XI 0.23, CI: 0.14-0.33).
Among 153 healthy premenopausal women. factor IX levels
were substantially higher among women who used oral contracep-
lives compared with women who did not (mean difference: 22.7
U/dL, CI: 15.8-29.5. after age adjustment: 25.6 U/dL, CI: 18.0-33.2).
The time between thrombosis and the venipuncture did not
influence the levels of factor IX in the patients. After dividing the
intervening time into 4 periods, the factor IX levels remained
approximately the same, ranging from 113 U/dL in individuals with
a venipuncture within l year after the thrombosis (n = 108) to 111
U/dL in individuals with a venipuncture more than 3 years after
their thrombosis (n = 35).






























*At time of venipuncture, for 153 women in reproductive age (see "Materials and
methods" for selection criteria)
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Factor IX äs a risk factor for DVT
Ten percent of the heallhy control subjects had factor IX levels
above 129 U/dL (90th percentiie = 129 U/dL). More than 20% of
the patients had factor IX levels exceeding this cutoff point. which
implies that individuals with a factor IX level higher than 129 U/dL
had a more than 2-fold increased risk to develop DVT when
compared with individuals having factor IX levels below this cutoff
value (Table 2). After adjustment for age. sex. and oral contracep-
tive use. the OR was 2.8 (CI: 1.9-4.3). When adjustment included
factor VI I I . XI, and vilamin K-dependent clot t ing factor levels ( a l l
dichotomized at the 9üth percentiie), the OR was 2.0 (CI: l .3-3.2).
When adjustment only included the v i tamin K-dependent clot t ing
factors (factor II. VII, and X), the risk associated with factor IX
leve ls exceeding the 90th percentiie remained increased 2-fold
(OR: 2.0: CI: 1.3- 3.0). Additional adjustment for C-reactive
protein diel not affect the risk estimates.
A total of 130 patients and 51 control subjects had a known
genetic risk factor for thrombosis. Exclusion of these indiv iduals
only marginally affected the risk estimates (crude OR: 2.5, CI:
1.6-3.9; after adjustment for age, sex, and oral contraceptive use:
OR: 3.0. CI: 1.9-4.7; when adjustment included factor VIII. XI. and
vitamin K-dependent clolting factor levels: OR: 2.2. CI: l .3-3.6).
We used the 90th percentiie äs a cutoff point for the levels of
factor IX. When the 95th percentiie (Pg, = 142 U/dL) was used. the
crude OR was s l ight ly higher, at 2.5 (CI: 1.5-4.3). Table 3 shows
the risk of thrombosis for strata of factor IX levels. Table 3 shows
that there is a relationship between thrombosis and factor IX levels
(dose response). with a 3.2-fold increased risk for individuals with
Table 2. Crude odds ratlos for subgroups








Men (n =- 373)
Patients
Controls
Women (all) (n = 526)
Patients
Controls
Use of oral eontraceptives*
Yes (premenopausal) (n - 77)
Patients
Controls
No (premenopausal) (n = 130)
Patients
Controls
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1 3 (09-1 7)
2 1 (1 4-3.2)
3 2 (1.7-6 2)
AdjustedORt (95% CI)
r
1 3 ( 1 0-1 8)
2 7 ( 1 7-42)
48(23 -10 .1 )
'Reference category.
tOdds ratio (OR) adjusted for sex age. and oral contraceptive use at the time of
thrombosis äs well äs at the time of the venipuncture
factor IX levels over 150 U/dL compared with those having levels
below 100 U/dL.
Comparing younger and older subgroups ( w i t h the median age
äs a dhis ion) , the odds ratios were equal. a 2.5-fold increased risk
for high factor IX levels in the i n d i v i d u a l s aged under 45 and a
2.3-fold increased risk for the older people (Table 2).
When the risk of developing DVT is assessed for men and
women separately. äs shown in Table 2. we found a s l ight ly higher
relative risk in women than in men. Restricting the female
population to premenopausal women who did not use oral contra-
ception at the t ime of thrombosis (or s imilar date for the controls)
nor at the time of venipuncture. the relative risk increased to 12.4.
For women using oral eontraceptives both at the thrombotic event
and at the time of venipuncture. the relative risk was 1.5. whereas
for postmenopausal women the relative risk was 6.2.
For the analysis of the effect on the thrombotic risk of
combinations of factor VIII and factor IX levels. we used the 90th
percentiie (of the controls) äs cutoff points for both ( 1 5 1 lU/dL for
factor VIII and 129 U/dL for factor IX) (Table 4). Although a high
level of factor VIII and a high le \el of factor IX each contribute to
the risk of developing DVT. the risk is highest when both clotting
factor levels are above the 90th percentiie (8 times higher than
when both clotting factor levels are below the 90th percentiie, CI:
3.6-18.4).
Discussion
Individuals who have high l eve l s of factor IX (> 129 U/dL) have a
more than 2-fold increased risk of developing a rirst DVT
compared with individuals having low levels of factor IX. The risk
of thrombosis increased with increasing plasma levels of factor IX
(dose response). At factor IX levels more than 125 U/dL. an
increase of the risk can already be observed compared with the
refcrence category (factor IX levels < 100 U/dL). Ind iv idua l s wilh
a factor IX level over 150 U/dL have a more than 3-fold increase m
the risk of thrombosis when compared w i t h the reference categorv
Deep vein thrombosis is more often seen in women than in
men." Blood groups other than O. äs well äs increasing age.
increase the risk of developing DVT. which was reviewed in























2 2 (1 4-3 3)
1 6 (1 0-2 5)
8.2(36-184)
"At time of thrombosis (or similar index date for controls) äs well äs at time of
venipuncture (16 of the 153 premenopausal women mentioned earlier changed their
oral contraceptive use and were therefore excluded from this analysis).
High means above 90th percentiie low means below 90th percentiie (of the
control subiects)
The90th percentileof factor IX and factor VIII, respectively, (measured in control
subiects): 129 U/dL and 151 lU/dL
•Reference category
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several studies.'4·26-" Our observations that factor IX levels
increase with age and with oral contraceptive use are in accordance
with earlier studies.2 '~2S However. the OR for high levels of factor
IX adjusted for these factors did not differ from the crude OR,
which means that the risk associated with high levels of factor IX is
not explained by these other factors nor by other thrombophilic
abnormalities, äs shown by restriction to individuals without these
abnormalities.
It is not likely that the factor IX levels changed äs a conse-
quence of the thrombosis because factor IX is not an acute-phase
reactant; venipuncture was at least 6 months after the event, and no
effect of the time elapsed between thrombosis and venipuncture on
factor IX levels was observed; also, adjustment for C-reactive
protein did not affect the results.
Age had no effect on the relative risk of DVT caused by
elevated levels of factor IX. which implies a larger absolute effect
in older age groups where thrombosis is more common man among
younger individuals.
The relative risk appeared highest in postmenopausal women
(6-fold increased risk) and premenopausal women who did not use
oral contraceptives (12-fold increased risk). This high relative risk
in women not using oral contraceptives contrasts to previous
findings on other abnormalities of the clotting System, where the
risk was highest in women who used oral contraceptives.3" For
example. the factor V Leiden mutalion causes a 7- to 8-fold
increase of the risk among both nonusers of oral contraceptives and
women who do use oral contraceptives. Because use of oral
contraceptives increases the risk 4-fold. the risk in carriers of factor
V Leiden mutation who used oral contraceptives was about 30 times
higher than the risk in a nonuser who did not carry the mutation.1"
In this study we found. however. that the risk associated with
elevated factor IX levels was highest in women who did not use
oral contraceptives. An explanation for this Unding could be a
ceiling value for the factor IX levels: that is, in women who have a
tendency to increased factor IX levels. oral contraceptives do not
cause additional increases. This is explained in Figure 1. Compar-
ing the healthy premenopausal control women in Figure l (groups
2 and 4). one can see that oral contraceptive use causes the factor
IX levels to rise. Figure l also shows that the factor IX levels in
premenopausal patients (groups l and 3) are about equal. regard-
less of theiroral contraceptive use. In female patients the factor IX
levels, therefore, do not seem to increase when they use oral
contraceptives, whereas they do increase in healthy female con-
trols. In the group of women who use oral contraceptives (groups l
and 2), the factor IX levels of patients and eontrols are therefore
closer together. which decreases the estimated relative risk.
This docs not mean that oral contraceptives act protectively
against the risk of DVT due to elevated levels of factor IX. It may
be. however, that in women who already have elevated levels of
factor IX. the use of oral contraceptives does not contribute further
to the risk of DVT associated with increased levels of factor IX.
Another explanation is Chance. Compared with women who did not
use oral contraceptives and had Iow factor IX levels, those who had
high factor IX levels and did not use oral contraceptives had a









premenop, OC+ postmenop. OC-
premenop, OC-
Figure 1. Comparison of the factor IX levels in premenopausal and postmeno-
pausal women. Factor IX antigen levels are shown (median, interquartile ränge, and
ränge); OC- refers to oral contraceptive use both at the time of thrombosis and at the
time of venipuncture; OC— refers to nonusers of oral confraceptives (both at the time
of ihrombosis and at the time of the venipuncture); premenop and postmenop refer to
premenopausal and postmenopausal, respectively. Group 1. premenopausal pa-
tients using oral contraceptives (n - 30: median - 116 U/dL): group 2 premeno-
pausal healthy controis using oral contraceptives (n = 47; median = 112 U/dL);
group 3' premenopausal patients not using oral contraceptives (n = 40; me-
dian = 110 U/dL); group 4: premenopausal healthy controis not using oral contracep-
tives (n -- 90, median = 91 U/dL); group 5: postmenopausal patients not using oral
contraceptives (n - 60; median = 119 U/dL); group 61 postmenopausal controis not
using oral contraceptives (n ·- 88; median = 105 U/dL)
those who used oral contraceptives and had high factor IX levels
had a 3.3-fold increased risk (CI: l .2-8.9). The conh'dence intervals
ofthose estimates show a fairly large overlap.
The results of this study indicate that an elevated level of factor
IX is a common risk factor for DVT. The relative risk of thrombosis
of 2.3 caused by high levels of factor IX (> 129 U/dL) is present in
10% of the population. This implies that high levels of factor IX are
responsible for a considerable number of thromboses.
The development of DVT is the result of several interactions
between genetic and environmcntal components.s·'' The role of
factor VIII äs a risk factor of DVT was described earlier.14 We
found that bolh factor VIII and factor IX levels contribute to the
risk of DVT. When both coagulation factors are elevated. however.
the risk of DVT is highest. At present. the molecular basis of
elevated factor IX levels is unknown (genetic. aequired. or a
combination of both). More studies need to be done to find out what
causes factor IX levels to be hish or Iow.
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